ArticleAnnals of intensive care2026
Early red blood cell transfusion burden, hemoglobin at first transfusion, and in-hospital mortality in patients supported with veno-arterial ECMO: a multicenter cohort study.
Article in Annals of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Red blood cell (RBC) transfusion is common during venoarterial extracorporeal membrane oxygenation (VA-ECMO), but the prognostic relevance of early cumulative transfusion burden and hemoglobin (Hb) at transfusion initiation remains uncertain. We examined associations of ECMO day-1 RBC dose and, among transfused patients, first-transfusion Hb and transfusion-pattern phenotype with in-hospital mortality. Methods: Adults aged ≥18 years initiating peripheral VA-ECMO at six Korean centers between January 2018 and March 2025 were analyzed. The primary analysis used a 24 -h landmark cohort of patients alive and still receiving ECMO beyond 24 h. Day-1 RBC dose was categorized as 0, 1-2, 3-4, or ≥5 units and modeled per 2-unit increase. Adjusted risk ratios (RRs) were estimated using modified Poisson regression. Secondary analyses assessed first-transfusion Hb and consistent- versus variable threshold phenotypes among transfused complete cases. Results: Among 2,020 included patients, 1,708 entered the 24-h landmark cohort, and 1,140 complete cases comprised the adjusted primary analysis. Compared with no day-1 transfusion, adjusted RRs for in-hospital mortality were 1.20 (95% confidence interval [CI], 1.02-1.40) for 1-2 units, 1.37 (95% CI, 1.17-1.59) for 3-4 units, and 1.48 (95% CI, 1.28-1.71) for ≥5 units. Each 2-unit increase was associated with higher mortality (adjusted RR, 1.08; 95% CI, 1.05-1.11), with concordant findings over ECMO days 1-2 (adjusted RR, 1.06; 95% CI, 1.04-1.08). Among 1,043 transfused complete cases with qualifying pretransfusion Hb, each 1 g/dL decrease in first-transfusion Hb was associated with higher mortality (adjusted RR, 1.15; 95% CI, 1.10-1.20). The association was evident in the consistent-threshold phenotype (adjusted RR, 1.16; 95% CI, 1.10-1.22) but not in the variable-threshold phenotype (adjusted RR, 1.02; 95% CI, 0.92-1.12). Conclusions: In adults receiving peripheral VA-ECMO, early RBC transfusion burden showed a graded association with in-hospital mortality, whereas lower first-transfusion Hb was a prognostic marker chiefly within the consistent-threshold phenotype. These findings support dose- and threshold-aware prognostic assessment but do not establish causality or define an optimal transfusion threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.